SiCap wakes up consumers
ALBANY, N.Y. SiCap, makers of Sinus Buster capsaicin nasal spray, last week announced a new capsaicin-based energy spray called Spray Awake. According to the manufacturer, Spray Awake delivers caffeine in small, sustained amounts to reap positive results without the unwanted side effects associated with energy drinks, shots or pills.
“Oral sprays are the most efficient way to deliver sustained energy without jitters or a crash,” stated Scott Latella, SiCap director of sales. “The key is to ingest caffeine in small, sustained doses under the tongue so it doesn’t get broken down in the body. This exclusive Spray Awake formula provides a natural time-release element for caffeine delivery.”
Spray Awake uses a capsaicin extract to deliver sustained doses of caffeine in a sublingual dose. Capsaicin is derived from hot peppers, and it’s known to create super-permeability through the mucous membranes, the manufacturer stated.
“Although the capsaicin in Spray Awake is derived from peppers, it’s not spicy or overwhelming,” noted Wayne Perry, SiCap director of innovations. “This natural formula tastes like mint. The capsaicin actually soothes your mouth and throat while also quenching your thirst.”
Poll shows lack of access to H1N1 vaccine
BOSTON A new national poll from Harvard School of Public Health that researchers released Friday found that a majority of adults who tried to get the H1N1 vaccine for themselves or their children have been unable to do so.
Since the H1N1 flu vaccine became available in October, 17% of American adults, 41% of parents and 21% of high-priority adults have tried to get it. Among adults who tried to get it for themselves, 70% were unable to get it. Among parents who tried to get the H1N1 vaccine for their children, 66% were unable to get it. Among high-priority adults who tried to get the H1N1 vaccine, 66% were unable to get it.
The poll also showed that some people were not able to find information about the location of available H1N1 flu vaccine. Approximately half (49%) who tried to find such information were unable to find it.
“These findings suggest that the nationwide H1N1 vaccine shortage is presenting a real challenge for those who have tried to get the vaccine,” stated Robert Blendon, professor of Health Policy and Political Analysis at HSPH, who co-directed the poll.
The poll suggested that nearly a third (29%) of those who have tried and could not get the vaccine (either for themselves or for their children) are very frustrated. That said, most who have tried and not been able to get it yet (91%) say they will try again this year to get the vaccine for themselves, their children or both.
“Public health officials who are encouraging H1N1 vaccination may be relieved to see that most people who have so far been unable to get the vaccine say they will try again,” said Blendon.
The poll, which examined the American public’s response to the H1N1 vaccine shortage, is the fifth in a series of surveys of public views concerning the H1N1 flu outbreak undertaken by the Harvard Opinion Research Program at HSPH. The polling was done Oct. 30 to Nov. 1.
McNeil announces voluntary recall of Tylenol product
FORT WASHINGTON, Pa. In consultation with the Food and Drug Administration, McNeil Consumer Healthcare on Friday initiated a voluntary recall of a limited number of product lots of Tylenol arthritis pain caplet 100-count bottles, with the distinctive red Ez-Open cap.
McNeil is initiating the recall after identifying an uncharacteristic smell or taste associated with these lots that led to a small number of consumers reporting nausea and related symptoms. This recall includes five product lots only and does not include any other lots of Tylenol analgesics. McNeil is implementing this recall as a precaution.
The affected Tylenol arthritis pain caplet 100-count product lot numbers can be found on the side of the bottle label. The affected product lot numbers are: 08BMC013, 08BMC020, 09BMC034, 09CMC036 and 09CMC040.